Dendritic- cells (DCs) have received considerable attention as potential targets for the development of anticancer vaccines. DC-based anticancer vaccination relies on patient-derived DCs pulsed with a source of tumor-associated antigens (TAAs) in the context of standardized maturation-cocktails, followed by their reinfusion. Extensive evidence has confirmed that DC-based vaccines can generate TAA-specific, cytotoxic T cells. Nonetheless, clinical efficacy of DC-based vaccines remains suboptimal, reflecting the widespread immunosuppression within tumors. Thus, clinical interest is being refocused on DC-based vaccines as combinatorial partners for T cell-targeting immunotherapies. Here, we summarize the most recent preclinical/clinical development of anticancer DC vaccination and discuss future perspectives for DC-based vaccines in immuno-oncology.
Author Info:
(1) Cell Death Research & Therapy (CDRT) unit, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium. (2) Department of Oncology, Laboratory of Tumor Immunology a
nd Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven Cancer Institute, Leuven, Belgium. (3) Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven Cancer Institute, Leuven, Belgium. Department of Gynecology and Obstetrics, UZ Leuven, Leuven, Belgium. (4) Cell Death Research & Therapy (CDRT) unit, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium. Center for Cancer Biology (CCB), VIB, Leuven, Belgium. (5) Research Group Experimental Neurosurgery and Neuroanatomy, KU Leuven, Leuven, Belgium. Department of Neurosurgery, UZ Leuven, Leuven, Belgium. (6) Gustave Roussy Comprehensive Cancer Institute, Villejuif, France. INSERM, Villejuif, France. Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France. Universite Paris Sud/Paris XI, Le Kremlin-Bicetre, France. (7) Equipe labellisee par la Ligue contre le cancer, Universite de Paris, Sorbonne Universite, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France. Pole de Biologie, Hopital Europeen Georges Pompidou, AP-HP, Paris, France. Suzhou Institute for Systems Medicine, Chinese Academy of Sciences, Suzhou, China. Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden. (8) Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. Sandra and Edward Meyer Cancer Center, New York, NY, USA. Department of Dermatology, Yale School of Medicine, New Haven, CT, USA. Universite de Paris Descartes, Paris, France. (9) Cell Death Research & Therapy (CDRT) unit, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium.
